It’s raining cats and dogs at Bulgarian food & nutrition major Huvepharma. ‘Companion animals’, says O.P. Singh, managing director of the global giant’s subsidiary Huvepharma SEA, are the fastest-growing segment for the company, with a growth rate of 27 per cent year on year in India. “This is second only to Japan, which is growing at 29 per cent, and more than double the global growth of about 12 per cent,” he adds. India is one of the most important of the 90-plus countries in six continents in which Huvepharma operates. The global market for this segment is over Rs2,000 crore annually for food and Rs380 crore for health supplements. “Pets have the same lifestyle problems as humans: cancer, diabetes, hypertension and so on,” says Singh. This is why I started my first pet nutrition and health company, Petcare. It was literally a bedroom idea, because I had a dog that had been gifted to me by the Maharaja of Bhutan.” He later sold Petcare to Cargill Foods, and later started Venkys Pet for Venkateshwara Hatcheries – followed in 2019 by Opuspet. The market continues to grow healthily, he says: the pet adoption rate is growing at 30 per cent a year. Singh has been a part of the animal health industry for almost four decades now, he acknowledges. “The industry has come a long way in terms of amalgamation, understanding of the evolving demands of livestock, balancing act between productivity and animal health, understanding of consumer behaviour,” he says. “All this, supported by advanced technological knowhow, investment in research and product development, has put us on the road to achieving improved efficiencies in poultry health and management.” Overall, India makes up a 3-per-cent share in the global animal health market. Livestock, which contributes 4.5 per cent to the country’s overall GDP, comprises the largest chunk – as much as half -- of the animal healthcare market, followed by poultry at 40 per cent. The company with responsibility In what is undoubtedly an agri-business-dependent economy, Huvepharma sees it as its responsibility, as animal healthcare providers, to create a ‘sustainable and regenerative ecosystem’. And so, Singh says, all the five businesses he heads – Huvepharma SEA; nutrition and enzyme technology company Advanced Bio-Agro Tech Ltd (ABTL); Huvepharma SEA; Norel NBPL, which is a joint venture with Norel of Spain; and Opuspet, a company he launched in 2018 – are fashioned around this thought. The five have a combined turnover of €74 million (Rs653.17 crore). “No resource can be inexhaustible or its usage without repercussions; so, our team has also been involved in research and potential application of alternative protein in animal feed,” he explains. Pilot projects for this have been conducted globally and even commercial usage is underway in some instances. But he and his team are looking for solutions that are feasible, available, accessible, efficient, workable for multi-species and cost-effective in the Indian context. “It’s a tall order, but we are chipping away at it with patience and perseverance. My team and I do our best to stay on course,” he says. Stressing the importance of local know-how and veterinarian connect for successful India operations, Singh says it is this, blended with the Bulgarian parent’s international expertise, which had enabled the Indian entities to introduce products that are specific and customised to meet the unique demand of different species as well as geographies.